Cargando…

In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts

Pancreatic cancer is a devastating disease often detected at later stages, necessitating swift and effective chemotherapy treatment. However, chemoresistance is common and its mechanisms are poorly understood. Here, label-free multi-modal nonlinear optical microscopy was applied to study microstruct...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jaena, Sorrells, Janet E., Chaney, Eric J., Abdelrahman, Amro M., Yonkus, Jennifer A., Leiting, Jennifer L., Nelson, Heidi, Harrington, Jonathan J., Aksamitiene, Edita, Marjanovic, Marina, Groves, Peter D., Bushell, Colleen, Truty, Mark J., Boppart, Stephen A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520051/
https://www.ncbi.nlm.nih.gov/pubmed/37749184
http://dx.doi.org/10.1038/s42003-023-05368-y
_version_ 1785109827892019200
author Park, Jaena
Sorrells, Janet E.
Chaney, Eric J.
Abdelrahman, Amro M.
Yonkus, Jennifer A.
Leiting, Jennifer L.
Nelson, Heidi
Harrington, Jonathan J.
Aksamitiene, Edita
Marjanovic, Marina
Groves, Peter D.
Bushell, Colleen
Truty, Mark J.
Boppart, Stephen A.
author_facet Park, Jaena
Sorrells, Janet E.
Chaney, Eric J.
Abdelrahman, Amro M.
Yonkus, Jennifer A.
Leiting, Jennifer L.
Nelson, Heidi
Harrington, Jonathan J.
Aksamitiene, Edita
Marjanovic, Marina
Groves, Peter D.
Bushell, Colleen
Truty, Mark J.
Boppart, Stephen A.
author_sort Park, Jaena
collection PubMed
description Pancreatic cancer is a devastating disease often detected at later stages, necessitating swift and effective chemotherapy treatment. However, chemoresistance is common and its mechanisms are poorly understood. Here, label-free multi-modal nonlinear optical microscopy was applied to study microstructural and functional features of pancreatic tumors in vivo to monitor inter- and intra-tumor heterogeneity and treatment response. Patient-derived xenografts with human pancreatic ductal adenocarcinoma were implanted into mice and characterized over five weeks of intraperitoneal chemotherapy (FIRINOX or Gem/NabP) with known responsiveness/resistance. Resistant and responsive tumors exhibited a similar initial metabolic response, but by week 5 the resistant tumor deviated significantly from the responsive tumor, indicating that a representative response may take up to five weeks to appear. This biphasic metabolic response in a chemoresistant tumor reveals the possibility of intra-tumor spatiotemporal heterogeneity of drug responsiveness. These results, though limited by small sample size, suggest the possibility for further work characterizing chemoresistance mechanisms using nonlinear optical microscopy.
format Online
Article
Text
id pubmed-10520051
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-105200512023-09-27 In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts Park, Jaena Sorrells, Janet E. Chaney, Eric J. Abdelrahman, Amro M. Yonkus, Jennifer A. Leiting, Jennifer L. Nelson, Heidi Harrington, Jonathan J. Aksamitiene, Edita Marjanovic, Marina Groves, Peter D. Bushell, Colleen Truty, Mark J. Boppart, Stephen A. Commun Biol Article Pancreatic cancer is a devastating disease often detected at later stages, necessitating swift and effective chemotherapy treatment. However, chemoresistance is common and its mechanisms are poorly understood. Here, label-free multi-modal nonlinear optical microscopy was applied to study microstructural and functional features of pancreatic tumors in vivo to monitor inter- and intra-tumor heterogeneity and treatment response. Patient-derived xenografts with human pancreatic ductal adenocarcinoma were implanted into mice and characterized over five weeks of intraperitoneal chemotherapy (FIRINOX or Gem/NabP) with known responsiveness/resistance. Resistant and responsive tumors exhibited a similar initial metabolic response, but by week 5 the resistant tumor deviated significantly from the responsive tumor, indicating that a representative response may take up to five weeks to appear. This biphasic metabolic response in a chemoresistant tumor reveals the possibility of intra-tumor spatiotemporal heterogeneity of drug responsiveness. These results, though limited by small sample size, suggest the possibility for further work characterizing chemoresistance mechanisms using nonlinear optical microscopy. Nature Publishing Group UK 2023-09-25 /pmc/articles/PMC10520051/ /pubmed/37749184 http://dx.doi.org/10.1038/s42003-023-05368-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Park, Jaena
Sorrells, Janet E.
Chaney, Eric J.
Abdelrahman, Amro M.
Yonkus, Jennifer A.
Leiting, Jennifer L.
Nelson, Heidi
Harrington, Jonathan J.
Aksamitiene, Edita
Marjanovic, Marina
Groves, Peter D.
Bushell, Colleen
Truty, Mark J.
Boppart, Stephen A.
In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts
title In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts
title_full In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts
title_fullStr In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts
title_full_unstemmed In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts
title_short In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts
title_sort in vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520051/
https://www.ncbi.nlm.nih.gov/pubmed/37749184
http://dx.doi.org/10.1038/s42003-023-05368-y
work_keys_str_mv AT parkjaena invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT sorrellsjanete invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT chaneyericj invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT abdelrahmanamrom invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT yonkusjennifera invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT leitingjenniferl invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT nelsonheidi invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT harringtonjonathanj invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT aksamitieneedita invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT marjanovicmarina invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT grovespeterd invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT bushellcolleen invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT trutymarkj invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts
AT boppartstephena invivolabelfreeopticalsignaturesofchemotherapyresponseinhumanpancreaticductaladenocarcinomapatientderivedxenografts